论文部分内容阅读
[目的]探讨miR-21在骨肉瘤中的表达并分析其与临床病理之间的联系。[方法]本文通过实时定量PCR方法检测42例骨肉瘤组织(包括12例来自同一患者的原发骨肉瘤组织和转移肿瘤组织)和来自同一患者的邻近正常骨组织中miR-21的表达并评估miR-21的临床相关性。[结果]miR-21在所有的组织中都有表达,且在肿瘤组织中比在正常组织中有明显的高表达(P=0.013),此外,miR-21在转移的肿瘤组织中比在同一样本中的原发肿瘤组织中高表达(P=0.002),另外,miR-21高表达的患者有着显著更差预后(P=0.016)。[结论]miR-21高表达潜在的导致转移,其可以作为骨肉瘤患者预后的一个指标。
[Objective] To investigate the expression of miR-21 in osteosarcoma and analyze its relationship with clinical pathology. [Method] The expression of miR-21 in 42 cases of osteosarcoma tissue (including 12 cases of primary osteosarcoma tissue and metastasized tumor tissue from the same patient) and adjacent normal bone tissue from the same patient were detected by real-time quantitative PCR method and evaluated Clinical relevance of miR-21. [Results] miR-21 was expressed in all tissues and was significantly higher in tumor tissues than in normal tissues (P = 0.013). In addition, miR-21 was more expressed in metastatic tumor tissues than in the same The samples were highly expressed in primary tumor tissues (P = 0.002). In addition, patients with high miR-21 expression had a significantly worse prognosis (P = 0.016). [Conclusion] The high expression of miR-21 potentially leads to metastasis, which can be used as an indicator of the prognosis of patients with osteosarcoma.